Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1624 1625
This examiner grants 65% of resolved cases
Phillip Matthew Rzeczycki is an examiner in Tech Center 1600 and Art Unit 1621. The examiner has 128 resolved cases. The allowance rate for these matters is 64.8%. This metric provides a baseline for the likelihood of securing a patent grant during prosecution. The 64.8% rate is a primary data point for evaluating the probability of success in this specific Art Unit.
The interview lift is 37.0%. This value measures the increase in the probability of allowance following an interview. A lift of 37.0% indicates that engaging in a direct dialogue with the examiner can be a productive strategy. Practitioners should weigh this 37.0% figure when deciding whether to request a formal interview for their 128 resolved cases.
The median days to allowance is 1251. This figure represents the typical time span from filing to the issuance of a patent. A median of 1251 days informs the scheduling and budget expectations for applicants. This 1251 days duration is a factor in the overall prosecution timeline.
In Tech Center 1600, the examiner's 64.8% allowance rate and 128 resolved cases define the current landscape. The interview lift serves as a tool for navigating the prosecution process toward a grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19559874 | Substituted 2-(Pyrrolidine-3-yl)acetic Acid Derivative, Preparation Method and Use Thereof | Final Rejection | Innovstone Therapeutics Limited |
| 18277748 | UNSYMMETRIC LINEAR CARBONATE AND METHOD FOR PREPARING THEREOF | Final Rejection | LG CHEM, LTD. |
| 19308717 | RAS INHIBITORS | Non-Final OA | Revolution Medicines, Inc. |
| 18294422 | PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | Non-Final OA | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY |
| 17759817 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | Final Rejection | Board of Regents, The University of Texas System |
| 18002477 | Methods of Treating, Ameliorating, Shortening Duration, and/or Reversing Symptoms and/or Complications of a Coronavirus Infection | Final Rejection | Yale University |
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | Final Rejection | Health Research, Inc. |
| 18283704 | USE OF MEBENDAZOLE FOR TREATING VIRAL INFECTION | Final Rejection | Skymount Medical US Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy